

Clinical Policy: Idursulfase (Elaprase)

Reference Number: CP.PHAR.156

Effective Date: 02.01.16

Last Review Date: 05.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Idursulfase (Elaprase[®]) is a hydrolytic lysosomal glycosaminoglycan-specific enzyme.

FDA Approved Indication(s)

Elaprase is indicated for the treatment of patients with Hunter syndrome (mucopolysaccharidosis [MPS] II).

Elaprase has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with Elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of Elaprase have not been established in pediatric patients less than 16 months of age.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Elaprase is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Mucopolysaccharidosis II: Hunter Syndrome (must meet all):

1. Diagnosis of MPS II (Hunter syndrome) confirmed by one of the following (a or b):
 - a. Enzyme assay demonstrating a deficiency of iduronate 2-sulfatase activity;
 - b. DNA testing;
2. Age \geq 16 months;
3. Documentation of member's current weight (in kg);
4. Dose does not exceed 0.5 mg/kg per week.

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):

- a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
- b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Mucopolysaccharidosis II: Hunter Syndrome (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by improvement in the individual member's MPS II (Hunter syndrome) manifestation profile including any of the following: percent predicted FVC, 6-minute walk test, splenomegaly, diarrhea, joint stiffness, growth deficiencies;
3. Documentation of member's current weight (in kg);
4. If request is for a dose increase, new dose does not exceed 0.5 mg/kg per week.

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or

CLINICAL POLICY

Idursulfase

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

FVC: forced vital capacity

MPS II: mucopolysaccharidosis II

6MWT: 6-minute walk test

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported.
- Boxed warning(s): risk of life-threatening anaphylactic reactions with Elaprase infusions.

Appendix D: General Information

- A 10% relative improvement over baseline in the percent predicted forced vital capacity (FVC) is considered by the American Thoracic Society to be a clinically significant change and not due to week-to-week variability.
- In the clinical trials of Elaprase in patients ≥ 5 years of age, patients treated with Elaprase demonstrated a 35 meter mean increase relative to placebo in the 6-minute walk test (6MWT) after 53 weeks.
- The presenting symptoms and clinical course of MPS II can vary from one individual to another. Some examples, however, of improvement in MPS II disease as a result of Elaprase therapy may include improvement in:
 - Percent predicted FVC
 - 6-minute walk test
 - Splenomegaly
 - Diarrhea
 - Joint stiffness
 - Growth deficiencies

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
MPS II	0.5 mg/kg IV every week	Based on weight

CLINICAL POLICY
Idursulfase

VI. Product Availability

Single-use vial: 6 mg/3 mL

VII. References

1. Elaprase Prescribing Information. Lexington, MA: Shire Human Genetic Therapies, Inc.; February 2025. Available at <http://www.elaprase.com>. Accessed January 13, 2026.
2. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. *J Pediatr.* 2004; 144(5 Suppl): S27-S34.
3. McBride KL, Berry SA, Braverman N. Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genetics in Medicine.* 2020;22:1735-42.
4. Stapleton M, Hoshina H, Sawamoto K, et al. Critical review of current MPS guidelines and management. *Molecular Genetics and Metabolism.* 2019;126:238-45.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1743	Injection, idursulfase, 1 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2022 annual review: no significant changes; added requirement for documentation of member’s current weight for dose calculation purposes; referenced reviewed and updated..	02.26.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	09.30.22	
2Q 2023 annual review: no significant changes; references reviewed and updated.	02.07.23	05.23
2Q 2024 annual review: no significant changes; references reviewed and updated.	01.09.24	05.24
2Q 2025 annual review: no significant changes; references reviewed and updated.	03.10.25	05.25
2Q 2026 annual review: no significant changes; updated initial approval duration from 6 months to 12 months; for Continued Therapy added examples of positive treatment response that were already outlined in Appendix D and previously referred to within the criteria; references reviewed and updated. Added ICHRA line of business.	04.10.26	05.26

CLINICAL POLICY

Idursulfase

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members

CLINICAL POLICY**Idursulfase**

and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.